查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917696

短肠症候群市场－2026-2031年预测

Short Bowel Syndrome Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 153 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计短肠症候群市场将从 2025 年的 19.53 亿美元成长到 2031 年的 29.06 亿美元，复合年增长率为 6.85%。

受临床、商业性和监管因素的共同影响，短肠症候群(SBS) 市场预计将稳定成长。市场扩张主要与患者群体不断扩大、临床认知度不断提高以及治疗性介入管线不断推进密切相关。儘管全部区域预计都将实现成长，但市场发展轨迹仍受到商业性和研究环境中许多机会和挑战的双重影响。

市场成长的主要催化剂是全球胃肠道疾病盛行率的上升，而这些疾病正是短肠症候群（SBS）的主要病因。克隆氏症、肠扭转和其他严重的肠道疾病通常需要大规模的手术切除，导致肠道功能障碍。这些基础疾病发生率的上升（部分原因是生活方式的改变）直接扩大了可接受SBS治疗的患者群体。这持续催生了对有效治疗策略的临床需求，进而推动了市场发展。

为配合此人口统计数据，各方正齐心协力提高医护人员与病患对疾病的认识。由专业组织和协会主导的宣传教育活动发挥关键作用，这些活动旨在教育相关人员了解肠道功能障碍、短肠综合征（SBS）给患者带来的巨大负担以及系统性护理过渡的重要性。透过改善诊断和治疗模式，这些努力显着提高了患者识别率、护理标准，并促进了现有和新兴治疗方法。

此外，市场发展得益于大量的科学研究和临床活动。政府和机构的资金支持着旨在开发创新治疗方法的先进研究计划，包括新型药物以及组织工程等突破性方法的研究。同时，由于大型製药和生技公司积极参与临床开发，市场竞争格局也十分活跃。多种在临床实验药物，包括长效类似物和其他标靶治疗，正处于研发阶段，这预示着治疗方法方向正朝着更有效、更便捷的方向发展。新药的商业化以及新型化合物获得监管部门核准预计将成为扩大治疗选择和市场规模的关键成长要素。

然而，市场潜力受到多种限制因素的限制。核准药物疗法的数量有限，尤其是在发展中地区，这限制了患者的用药途径。此外，某些药物的副作用需要仔细的临床评估，以确保患者获得良好的获益风险比。除了这些药理学的挑战外，不同地区医疗基础设施和报销制度的差异也是阻碍市场普遍渗透和资源匮乏地区成长的障碍。

从地理角度来看，北美预计将继续占据显着的市场份额。这一主导地位得益于短肠症候群（SBS）的高发生率、先进的医疗基础设施以及对生物医学研究的大力投入。该地区拥有许多积极投资于研究和临床试验的关键市场参与者，从而创造了有利于创新和商业发展的环境。该地区临床专业知识和研究资金的集中也持续吸引大量的市场活动。

总之，短肠症候群市场正处于成长轨道上，其成长动力源自于不断增长的临床需求和科学进步。伴随相关胃肠道疾病的患者群体不断扩大，为市场需求提供了坚实的基础。此外，策略性的宣传活动和积极的在临床实验治疗方案（由研究经费支持）也进一步强化了这项需求。市场相关人员正抓住机会，利用创新治疗方法满足尚未满足的重大需求，同时也努力应对药物可近性、安全性以及全球医疗保健差异等挑战。该市场的未来发展将取决于临床研究成果能否成功转化为核准、可及且耐受性良好的治疗方法，从而显着改善患者的治疗效果。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要企业的策略倡议，并了解透过正确的策略进入市场的可能性。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在动态环境中製定策略决策，发展新的商业机会和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

企业使用我们的报告的目的是什么？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯）及主要发展动态。

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章短肠症候群药物市场

  • 介绍
  • 类升糖素肽-2 (GLP2)
  • 生长激素
  • 麸酰胺酸
  • 其他的

第六章短肠症候群市场依通路划分

  • 介绍
  • 医院药房
  • 零售药房
  • 线上销售

第七章短肠症候群市场（按地区划分）

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第八章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第九章：公司简介

  • Takeda Pharmaceutical Company
  • OxThera Inc.
  • VectivBio AG
  • Merck KGaA
  • Ardelyx
  • Zealand Pharma
  • Nestle Health Science
  • Hanmi Pharm.Co., Ltd

第十章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615639

The short bowel syndrome market, at a 6.85% CAGR, is projected to increase from USD 1.953 billion in 2025 to USD 2.906 billion in 2031.

The Short Bowel Syndrome (SBS) market is poised for steady growth, driven by a confluence of clinical, commercial, and regulatory factors. The market's expansion is fundamentally linked to an increasing patient population, heightened clinical awareness, and a progressive pipeline of therapeutic interventions. While growth is anticipated across key regions, the market trajectory is influenced by both significant opportunities and inherent challenges that shape the commercial and research landscape.

A primary catalyst for market growth is the rising global prevalence of gastrointestinal disorders, which are a leading cause of SBS. Conditions such as Crohn's disease, volvulus, and other severe intestinal pathologies often necessitate extensive surgical resection, resulting in intestinal failure. The increasing incidence of these underlying disorders, partly attributed to evolving lifestyle factors, is directly enlarging the addressable patient pool for SBS therapies. This establishes a sustained clinical demand for effective management strategies, fueling market development.

Complementing this demographic driver is a concerted effort to elevate disease understanding among both healthcare providers and patients. Awareness initiatives, spearheaded by specialized organizations and professional societies, are playing a pivotal role. These programs focus on educating stakeholders about intestinal failure, the significant patient burden associated with SBS, and the importance of structured care transitions. By enhancing the diagnostic and treatment paradigm, these initiatives are instrumental in improving patient identification, care standards, and ultimately, the adoption of available and emerging therapies.

The market is further energized by significant scientific and clinical activity. Government and institutional funding is supporting advanced research projects aimed at developing innovative treatments. These include investigations into novel pharmacological agents as well as groundbreaking approaches like tissue engineering. Concurrently, the competitive landscape is dynamic, with key pharmaceutical and biotechnology companies actively engaged in clinical development. The pipeline features several investigational drugs, including long-acting analogs and other targeted therapies, indicating a move towards more effective and convenient treatment modalities. Product launches and the pursuit of regulatory approvals for new compounds are anticipated to be major growth levers, expanding treatment options and market scope.

However, the market's potential is tempered by several restraining factors. A limited number of approved pharmacotherapies, particularly in developing regions, constrains patient access. Furthermore, the side effect profiles associated with certain medications necessitate careful clinical evaluation to ensure a favorable benefit-risk ratio for patients. These pharmacological challenges, combined with disparities in healthcare infrastructure and reimbursement frameworks across different geographies, present barriers to universal market penetration and limit growth in under-resourced settings.

From a geographical perspective, North America is positioned to maintain a substantial market share. This prominence is underpinned by a well-established prevalence of SBS, advanced healthcare infrastructure, and robust investment in biomedical research. The region benefits from the presence of leading market players who are actively investing in research and clinical trials, fostering an ecosystem conducive to innovation and commercial development. The concentration of clinical expertise and research funding in this region continues to attract significant market activity.

In conclusion, the Short Bowel Syndrome market is on a growth trajectory shaped by increasing clinical need and scientific advancement. The expansion of the patient population due to related gastrointestinal disorders provides a solid foundation for demand. This is amplified by strategic awareness campaigns and a vibrant pipeline of investigational therapies supported by research funding. Market players are navigating a path defined by the opportunity to address a serious unmet medical need with innovative treatments, while simultaneously contending with challenges related to drug accessibility, safety, and global healthcare inequities. The evolution of this market will hinge on the successful translation of clinical research into approved, accessible, and well-tolerated therapies that meaningfully improve patient outcomes.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Short Bowel Syndrome Market Segmentation:

BY DRUG CLASS

  • Glucagon-like Peptide-2 (GLP2)
  • Growth Hormone
  • Glutamine
  • Others

BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

BY GEOGRAPHY

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SHORT BOWEL SYNDROME MARKET BY DRUG CLASS

  • 5.1. Introduction
  • 5.2. Glucagon-like Peptide-2 (GLP2)
  • 5.3. Growth Hormone
  • 5.4. Glutamine
  • 5.5. Others

6. SHORT BOWEL SYNDROME MARKET BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Hospital Pharmacies
  • 6.3. Retail Pharmacies
  • 6.4. Online Sales

7. SHORT BOWEL SYNDROME MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Takeda Pharmaceutical Company
  • 9.2. OxThera Inc.
  • 9.3. VectivBio AG
  • 9.4. Merck KGaA
  • 9.5. Ardelyx
  • 9.6. Zealand Pharma
  • 9.7. Nestle Health Science
  • 9.8. Hanmi Pharm.Co., Ltd

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations